Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$5.08 -1.4%	$7.00	$7.96 ▼ $24.15	$25.62M	0.63	15,685 shs	41,395 shs
AMGN Amgen	$335.83 +1.9%	$353.07	$261.43 ▼ $391.29	$181.39B	0.44	2.73 million shs	789,098 shs
BMY Bristol Myers Squibb	$56.79 +2.0%	$59.06	$42.52 ▼ $62.89	$116.02B	0.26	12.36 million shs	4.02 million shs
GILD Gilead Sciences	$136.86 +2.5%	$139.07	$97.86 ▼ $157.29	$170.04B	0.31	6.76 million shs	2.29 million shs
JSPR Jasper Therapeutics	$0.91 -3.0%	$1.04	$0.62 ▼ $7.19	$25.59M	3.07	559,997 shs	97,504 shs
NVS Novartis	$148.38 +2.2%	$152.36	$104.93 ▼ $170.46	$283.11B	0.46	2.05 million shs	538,770 shs
RCUS Arcus Biosciences	$24.60 -1.0%	$23.14	$7.91 ▼ $28.72	$3.10B	0.87	1.24 million shs	312,540 shs
VIGL Vigil Neuroscience	$8.05	$8.04	$1.75 ▼ $8.10	$383.91M	3.33	1.47 million shs	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	0.00%	-6.96%	-19.37%	-43.87%	+45.98%
AMGN Amgen	-0.64%	-0.07%	-6.08%	-9.61%	+23.97%
BMY Bristol Myers Squibb	-0.86%	-4.51%	-5.10%	-8.55%	+19.92%
GILD Gilead Sciences	+1.67%	+1.42%	-3.96%	-9.31%	+37.85%
JSPR Jasper Therapeutics	+1.72%	+1.28%	+17.44%	-28.08%	-79.15%
NVS Novartis	-0.60%	-1.06%	-5.72%	-8.31%	+33.52%
RCUS Arcus Biosciences	-2.01%	-3.34%	+11.56%	+19.83%	+200.30%
VIGL Vigil Neuroscience	0.00%	0.00%	0.00%	0.00%	+232.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$5.08 -1.4%	$7.00	$7.96 ▼ $24.15	$25.62M	0.63	15,685 shs	41,395 shs
AMGN Amgen	$335.83 +1.9%	$353.07	$261.43 ▼ $391.29	$181.39B	0.44	2.73 million shs	789,098 shs
BMY Bristol Myers Squibb	$56.79 +2.0%	$59.06	$42.52 ▼ $62.89	$116.02B	0.26	12.36 million shs	4.02 million shs
GILD Gilead Sciences	$136.86 +2.5%	$139.07	$97.86 ▼ $157.29	$170.04B	0.31	6.76 million shs	2.29 million shs
JSPR Jasper Therapeutics	$0.91 -3.0%	$1.04	$0.62 ▼ $7.19	$25.59M	3.07	559,997 shs	97,504 shs
NVS Novartis	$148.38 +2.2%	$152.36	$104.93 ▼ $170.46	$283.11B	0.46	2.05 million shs	538,770 shs
RCUS Arcus Biosciences	$24.60 -1.0%	$23.14	$7.91 ▼ $28.72	$3.10B	0.87	1.24 million shs	312,540 shs
VIGL Vigil Neuroscience	$8.05	$8.04	$1.75 ▼ $8.10	$383.91M	3.33	1.47 million shs	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	0.00%	-6.96%	-19.37%	-43.87%	+45.98%
AMGN Amgen	-0.64%	-0.07%	-6.08%	-9.61%	+23.97%
BMY Bristol Myers Squibb	-0.86%	-4.51%	-5.10%	-8.55%	+19.92%
GILD Gilead Sciences	+1.67%	+1.42%	-3.96%	-9.31%	+37.85%
JSPR Jasper Therapeutics	+1.72%	+1.28%	+17.44%	-28.08%	-79.15%
NVS Novartis	-0.60%	-1.06%	-5.72%	-8.31%	+33.52%
RCUS Arcus Biosciences	-2.01%	-3.34%	+11.56%	+19.83%	+200.30%
VIGL Vigil Neuroscience	0.00%	0.00%	0.00%	0.00%	+232.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVR AlloVir	0.00	N/A	N/A	N/A
AMGN Amgen	2.48	Hold	$357.12	6.34% Upside
BMY Bristol Myers Squibb	2.37	Hold	$61.31	7.96% Upside
GILD Gilead Sciences	2.86	Moderate Buy	$157.04	14.74% Upside
JSPR Jasper Therapeutics	2.42	Hold	$19.88	2,074.51% Upside
NVS Novartis	2.31	Hold	$141.20	-4.84% Downside
RCUS Arcus Biosciences	2.64	Moderate Buy	$33.33	35.50% Upside
VIGL Vigil Neuroscience	2.00	Hold	$8.00	-0.62% Downside

Current Analyst Ratings Breakdown

Latest GILD, AMGN, BMY, NVS, JSPR, VIGL, ALVR, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/11/2026	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $22.00
5/11/2026	GILD Gilead Sciences	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$170.00 ➝ $167.00
5/8/2026	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$175.00 ➝ $168.00
5/8/2026	GILD Gilead Sciences	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$148.00 ➝ $146.00
5/8/2026	GILD Gilead Sciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$155.00 ➝ $157.00
5/8/2026	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$123.00 ➝ $122.00
5/7/2026	AMGN Amgen	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/7/2026	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $34.00
5/5/2026	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/4/2026	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$351.00 ➝ $340.00
5/4/2026	RCUS Arcus Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
AMGN Amgen	$36.75B	4.93	$34.23 per share	9.81	$16.08 per share	20.88
BMY Bristol Myers Squibb	$48.19B	2.41	$8.22 per share	6.91	$9.09 per share	6.25
GILD Gilead Sciences	$29.44B	5.77	$10.91 per share	12.54	$18.23 per share	7.51
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A
NVS Novartis	$54.53B	5.19	$10.91 per share	13.60	$22.04 per share	6.73
RCUS Arcus Biosciences	$247M	12.53	N/A	N/A	$5.84 per share	4.21
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVR AlloVir	-$190.42M	-$20.23	N/A	N/A	N/A	N/A	-71.03%	-61.27%	N/A
AMGN Amgen	$7.71B	$14.37	23.39	14.30	3.33	20.96%	137.41%	13.28%	N/A
BMY Bristol Myers Squibb	$7.05B	$3.56	15.96	9.39	0.16	15.01%	64.87%	13.16%	7/30/2026 (Estimated)
GILD Gilead Sciences	$8.51B	$7.34	18.66	14.23	N/A	30.99%	48.19%	18.28%	N/A
JSPR Jasper Therapeutics	-$75.80M	-$4.60	N/A	N/A	N/A	N/A	-372.18%	-153.67%	N/A
NVS Novartis	$13.98B	$6.98	21.26	15.09	2.56	24.87%	38.82%	15.16%	7/21/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.18	N/A	N/A	N/A	-156.36%	-68.97%	-35.27%	N/A
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	N/A

Latest GILD, AMGN, BMY, NVS, JSPR, VIGL, ALVR, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	GILD Gilead Sciences	$1.91	$2.03	+$0.12	$1.61	$6.91 billion	$6.96 billion
5/5/2026	Q1 2026	RCUS Arcus Biosciences	-$0.92	-$1.02	-$0.10	-$1.02	$29.49 million	$17.00 million
4/30/2026	Q1 2026	AMGN Amgen	$4.77	$5.15	+$0.38	$3.34	$8.58 billion	$8.62 billion
4/30/2026	Q1 2026	BMY Bristol Myers Squibb	$1.42	$1.58	+$0.16	$1.31	$10.93 billion	$11.49 billion
4/27/2026	Q1 2026	NVS Novartis	$2.11	$1.99	-$0.12	$1.65	$13.44 billion	$13.52 billion
3/30/2026	Q4 2025	JSPR Jasper Therapeutics	-$0.79	-$0.3250	+$0.4650	-$0.32	N/A	N/A
2/25/2026	Q4 2025	RCUS Arcus Biosciences	-$1.11	-$0.89	+$0.22	-$0.89	$24.94 million	$33.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
AMGN Amgen	$10.08	3.00%	+8.27%	70.15%	14 Years
BMY Bristol Myers Squibb	$2.52	4.44%	+1.61%	70.79%	17 Years
GILD Gilead Sciences	$3.28	2.40%	+3.04%	44.69%	10 Years
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
NVS Novartis	$3.08	2.08%	+5.28%	44.13%	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Latest GILD, AMGN, BMY, NVS, JSPR, VIGL, ALVR, and RCUS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/7/2026	GILD Gilead Sciences	quarterly	$0.82	2.45%	6/15/2026	6/15/2026	6/29/2026
3/4/2026	AMGN Amgen	quarterly	$2.52	2.66%	5/15/2026	5/15/2026	6/5/2026
3/2/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.23%	4/2/2026	4/2/2026	5/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVR AlloVir	N/A	86.78	86.78
AMGN Amgen	5.65	1.26	1.01
BMY Bristol Myers Squibb	2.10	1.42	1.28
GILD Gilead Sciences	0.89	1.97	1.77
JSPR Jasper Therapeutics	N/A	2.62	2.62
NVS Novartis	0.96	0.85	0.65
RCUS Arcus Biosciences	0.19	4.04	4.04
VIGL Vigil Neuroscience	N/A	2.97	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVR AlloVir	66.05%
AMGN Amgen	76.50%
BMY Bristol Myers Squibb	76.41%
GILD Gilead Sciences	83.67%
JSPR Jasper Therapeutics	79.85%
NVS Novartis	13.12%
RCUS Arcus Biosciences	92.89%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
ALVR AlloVir	32.07%
AMGN Amgen	0.85%
BMY Bristol Myers Squibb	0.05%
GILD Gilead Sciences	0.30%
JSPR Jasper Therapeutics	4.60%
NVS Novartis	0.01%
RCUS Arcus Biosciences	9.60%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVR AlloVir	110	5.04 million	3.43 million	No Data
AMGN Amgen	31,500	539.68 million	535.10 million	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable
JSPR Jasper Therapeutics	20	28.00 million	26.71 million	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable
RCUS Arcus Biosciences	500	125.77 million	113.70 million	Optionable
VIGL Vigil Neuroscience	40	47.69 million	39.10 million	Not Optionable

GILD, AMGN, BMY, NVS, JSPR, VIGL, ALVR, and RCUS Headlines

Recent News About These Companies

Vigil Neuroscience Inc Merger and Leadership Changes

August 13, 2025 | theglobeandmail.com

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

July 14, 2025 | businesswire.com

Vigil Neuroscience, Inc. (VIGL) Cash Flow - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - Nasdaq

June 27, 2025 | nasdaq.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

June 25, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

June 9, 2025 | prnewswire.com

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Vigil Neuroscience halts Phase 2 trial for ALSP treatment

June 5, 2025 | investing.com

Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial

June 5, 2025 | biospace.comB

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...

June 5, 2025 | morningstar.comM

Disappointing results see Vigil Neuro drop iluzanebart development

June 4, 2025 | thepharmaletter.comT

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

June 4, 2025 | prnewswire.com

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

June 4, 2025 | globenewswire.com

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

June 2, 2025 | zacks.com

Stifel cuts Vigil Neuroscience stock rating, lowers target to $8

May 29, 2025 | investing.com

Stifel Downgrades Vigil Neuroscience (VIGL)

May 29, 2025 | msn.com

HC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)

May 28, 2025 | msn.com

Vigil Neuroscience Analyst Ratings and Price Targets | NASDAQ:VIGL | Benzinga

May 24, 2025 | benzinga.com

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil ...

May 24, 2025 | morningstar.comM

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL)

May 24, 2025 | financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD, AMGN, BMY, NVS, JSPR, VIGL, ALVR, and RCUS Company Descriptions

AlloVir NASDAQ:ALVR

$5.08 -0.07 (-1.36%)

As of 05/8/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Amgen NASDAQ:AMGN

$335.83 +6.24 (+1.89%)

As of 01:49 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Bristol Myers Squibb NYSE:BMY

$56.79 +1.12 (+2.02%)

As of 01:49 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Gilead Sciences NASDAQ:GILD

$136.86 +3.34 (+2.50%)

As of 01:49 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Jasper Therapeutics NASDAQ:JSPR

$0.91 -0.03 (-2.99%)

As of 01:25 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Novartis NYSE:NVS

$148.38 +3.15 (+2.17%)

As of 01:49 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Arcus Biosciences NYSE:RCUS

$24.60 -0.26 (-1.04%)

As of 01:49 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Vigil Neuroscience NASDAQ:VIGL

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GILD, AMGN, BMY, NVS, JSPR, VIGL, ALVR, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GILD, AMGN, BMY, NVS, JSPR, VIGL, ALVR, and RCUS Earnings

Compare Dividends

Latest GILD, AMGN, BMY, NVS, JSPR, VIGL, ALVR, and RCUS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GILD, AMGN, BMY, NVS, JSPR, VIGL, ALVR, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD, AMGN, BMY, NVS, JSPR, VIGL, ALVR, and RCUS Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools